Iceland· IS-EU/1/16/1112/001-002
Odefsey
A emtricitabine, tenofovir alafenamide and rilpivirine product containing emtricitabinum inn,rilpivirinum inn hýdróklóríð,tenofovirum alafenamidum inn fúmarat, registered in Iceland by Gilead Sciences Ireland UC*. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Emtricitabine, tenofovir alafenamide and rilpivirine is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AR19 (emtricitabine, tenofovir alafenamide and rilpivirine), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Emtricitabine, tenofovir alafenamide and rilpivirine · ATC J05AR19
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Emtricitabinum INN,Rilpivirinum INN hýdróklóríð,Tenofovirum alafenamidum INN fúmarat
- Manufacturer
- Gilead Sciences Ireland UC*
- Country
- Iceland (IS)
- ATC code
- J05AR19
- ATC class
- Emtricitabine, tenofovir alafenamide and rilpivirine
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean06722930 stk x1 glasISK 110208
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Emtricitabine, tenofovir alafenamide and rilpivirine in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEMTRICITABINE/RILPIVIRINE/TENOFOVIR ALAFENAMIDE VIATRISVIATRIS LIMITED, Dublin
- FinlandEmtricitabine/Rilpivirine/Tenofovir Alafenamide ViatrisViatris Limited
- PolandEmtricitabine/Rilpivirine/Tenofovir Alafenamide ViatrisViatris Ltd
- SwedenEmtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris 200 mg/25 mg/25 mg Filmdragerad tablettViatris Limited
- SpainEMTRICITABINA/RILPIVIRINA/TENOFOVIR ALAFENAMIDA VIATRIS 200 MG/25 MG/25 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGViatris Limited
- NorwayOdefseyAbacus Medicine A/S
- IrelandEmtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris 200 mg/25 mg/25 mg film-coated tabletsViatris Limited
- United StatesODEFSEYGilead Sciences, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris, Odefsey
- Norway · Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris, Odefsey
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/169e3c45-9ec7-4d55-b927-3a38413f6c34 GET /v1/drugs/169e3c45-9ec7-4d55-b927-3a38413f6c34?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "J05AR19",
"marketed": true,
"strength": "200 mg/25 mg/25 mg",
"ma_number": "EU/1/16/1112/001-002",
"substance": "Emtricitabinum INN,Rilpivirinum INN hýdróklóríð,Tenofovirum alafenamidum INN fúmarat",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í smitsjúkdómum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "42542"
}See everything about emtricitabine, tenofovir alafenamide and rilpivirine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.